Univariate analysis of engraftment, acute and chronic GVHD, DFS and Survival in 701 MDS patients that underwent allogeneic HCT from 2002-2006 by donor type
| . | MRD . | 8/8 MUD . | 7/8 MUD . | . | 8/8 MUD vs MRD . | 7/8 MUD vs MRD . | 7/8 MUD vs 8/8 MUD . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome . | N . | Probability (95% CI) . | N . | Probability (95% CI) . | N . | Probability (95% CI) . | P* . | P‡ . | P‡ . | P‡ . |
| ANC recovery | 176 | 413 | 112 | |||||||
| @ 28 d | 93 (89-96) | 92 (89-95) | 87 (79-92) | .21 | ||||||
| @ 100 d | 96 (93-99) | 96 (94-98) | 90 (84-95) | .09 | ||||||
| Platelets recovery (20 × 109/L) | 174 | 413 | 111 | |||||||
| @ 60 d | 86 (80-90) | 80 (75-83) | 76 (67-83) | .08 | ||||||
| @ 100 d | 86 (80-90) | 83 (79-86) | 77 (69-85) | .24 | ||||||
| Acute GVHD grade B-D | 176 | 413 | 111 | |||||||
| @ 100 d | 42 (35-49) | 54 (49-59) | 57 (48-67) | .009 | .006 | .009 | .52 | |||
| Acute GVHD grade C-D | 176 | 413 | 112 | |||||||
| @ 100 d | 21 (15-27) | 31 (27-36) | 30 (22-39) | .024 | .007 | .08 | .85 | |||
| Chronic GVHD | 171 | 400 | 110 | |||||||
| @ 1 y | 45 (38-53) | 47 (42-52) | 34 (25-43) | .033 | .66 | .055 | .009 | |||
| @ 3 y | 51 (43-59) | 49 (45-55) | 41 (32-51) | .25 | ||||||
| TRM | 175 | 413 | 112 | |||||||
| @ 1 y | 25 (18-31) | 32 (28-37) | 37 (28-46) | .06 | ||||||
| @ 3 y | 32 (25-39) | 40 (35-44) | 44 (34-53) | .08 | ||||||
| Relapse | 175 | 413 | 112 | |||||||
| @ 1 y | 25 (19-32) | 22 (19-27) | 24 (17-32) | .78 | ||||||
| @ 3 y | 30 (23-37) | 25 (21-29) | 28 (20-37) | .41 | ||||||
| DFS | 175 | 413 | 112 | .06† | ||||||
| @ 1 y | 50 (42-57) | 45 (40-50) | 40 (31-49) | .24* | ||||||
| @ 3 y | 38 (30-45) | 35 (30-40) | 28 (20-37) | .21* | ||||||
| Survival | 176 | 413 | 112 | .01† | ||||||
| @ 1 y | 57 (49-64) | 53 (48-58) | 46 (37-55) | .19* | ||||||
| @ 3 y | 44 (37-52) | 39 (34-44) | 29 (21-39) | .03* | .27 | .01 | .05 | |||
| . | MRD . | 8/8 MUD . | 7/8 MUD . | . | 8/8 MUD vs MRD . | 7/8 MUD vs MRD . | 7/8 MUD vs 8/8 MUD . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome . | N . | Probability (95% CI) . | N . | Probability (95% CI) . | N . | Probability (95% CI) . | P* . | P‡ . | P‡ . | P‡ . |
| ANC recovery | 176 | 413 | 112 | |||||||
| @ 28 d | 93 (89-96) | 92 (89-95) | 87 (79-92) | .21 | ||||||
| @ 100 d | 96 (93-99) | 96 (94-98) | 90 (84-95) | .09 | ||||||
| Platelets recovery (20 × 109/L) | 174 | 413 | 111 | |||||||
| @ 60 d | 86 (80-90) | 80 (75-83) | 76 (67-83) | .08 | ||||||
| @ 100 d | 86 (80-90) | 83 (79-86) | 77 (69-85) | .24 | ||||||
| Acute GVHD grade B-D | 176 | 413 | 111 | |||||||
| @ 100 d | 42 (35-49) | 54 (49-59) | 57 (48-67) | .009 | .006 | .009 | .52 | |||
| Acute GVHD grade C-D | 176 | 413 | 112 | |||||||
| @ 100 d | 21 (15-27) | 31 (27-36) | 30 (22-39) | .024 | .007 | .08 | .85 | |||
| Chronic GVHD | 171 | 400 | 110 | |||||||
| @ 1 y | 45 (38-53) | 47 (42-52) | 34 (25-43) | .033 | .66 | .055 | .009 | |||
| @ 3 y | 51 (43-59) | 49 (45-55) | 41 (32-51) | .25 | ||||||
| TRM | 175 | 413 | 112 | |||||||
| @ 1 y | 25 (18-31) | 32 (28-37) | 37 (28-46) | .06 | ||||||
| @ 3 y | 32 (25-39) | 40 (35-44) | 44 (34-53) | .08 | ||||||
| Relapse | 175 | 413 | 112 | |||||||
| @ 1 y | 25 (19-32) | 22 (19-27) | 24 (17-32) | .78 | ||||||
| @ 3 y | 30 (23-37) | 25 (21-29) | 28 (20-37) | .41 | ||||||
| DFS | 175 | 413 | 112 | .06† | ||||||
| @ 1 y | 50 (42-57) | 45 (40-50) | 40 (31-49) | .24* | ||||||
| @ 3 y | 38 (30-45) | 35 (30-40) | 28 (20-37) | .21* | ||||||
| Survival | 176 | 413 | 112 | .01† | ||||||
| @ 1 y | 57 (49-64) | 53 (48-58) | 46 (37-55) | .19* | ||||||
| @ 3 y | 44 (37-52) | 39 (34-44) | 29 (21-39) | .03* | .27 | .01 | .05 | |||